Completed PHASE4 INTERVENTIONAL 4-arm NCT00287677

Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients

Double Strategy to Induce and Expand the T Cell Repertoire by the Administration of Growth Hormone and Vaccination in HIV-1 Infected Patients

Sponsor: Carlos III Health Institute

Conditions HIV Infections

Interventions HAART Vaccination recombinant human Growth Hormone

Updated 5 times since 2017 Last updated: Nov 3, 2009 Started: Jan 31, 2006 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on HIV Infections, this trial is completed. The trial is conducted by Carlos III Health Institute and has accumulated 5 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Carlos III Health Institute
Germans Trias i Pujol Hospital
Hospital Clinic of Barcelona
Hospital General Universitario Gregorio Marañon

Data source: Germans Trias i Pujol Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Badalona, Spain
• Barcelona, Spain